Dr. John Cush RheumNow
1 year 9 months ago
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5
Dr. John Cush RheumNow
1 year 9 months ago
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Dr. John Cush RheumNow
1 year 9 months ago
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
https://t.co/sWawAgDgyS https://t.co/dVTb7QMFNj
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
Dr Ai Lyn Tan DrAiLynTan
1 year 9 months ago
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Dr. John Cush RheumNow
1 year 9 months ago
Biomarker substudy of #SLE Rx w/ low dose IL-2 Rx in 342 pts (40% responders). SRI-4 predicted by rash, proteinuria, uRBC, %CD4 T cells, C3 (AUC 0.9330; however renal markers did not correlate with achieving LLDAS. https://t.co/pDgwegbU6t https://t.co/72w4gNAiWt
Dr. John Cush RheumNow
1 year 9 months ago
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush RheumNow
1 year 9 months ago
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/cH4s99Fzka https://t.co/kNcUqahmeS
Dr. John Cush RheumNow
1 year 9 months ago
Retrospective population study of 383 #AS women who were pregnant (3.8/100,000) compared to controls. AS-Preg pts more likely to be older; White, w/ higher incomes, MORE thyroid Dz, Pregs, C-Sections, gestational DM, placenta previa, more neonatal SGA, IUFD… https://t.co/pgsmKgljwx https://t.co/IMJ8CTrqhY
Dr. John Cush RheumNow
1 year 9 months ago
Study of AutoAbs in 141 pts w/ systemic sclerosis overlap syndrome (SSc OS). Most common Abs: Ro-52, centromere (ACA) & anti-Scl-70. Scl-70 was assoc w/ ILD & SSc renal crisis (SRC); while ACA is protective factor of ILD. SRC & pulm HTN assoc w/ incr mortality… https://t.co/sqQhIlZjdB https://t.co/noyaFbd3Z8
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at conception, and secondary antiphospholipid syndrome. Pregnanci
Dr. John Cush RheumNow
1 year 9 months ago
US health expenditures grew from $4.1 trillion in 2020 to $4.5 trillion in 2022 (17.3% incr).
US saved >$400 billion in 2022 by using generic and biosimilar drugs, https://t.co/Z8kS4elyA3 https://t.co/3LopIiQiqZ
Dr. John Cush RheumNow
1 year 9 months ago
Claims study presented at SASM mtg by HSS orthopedists found among >100k Hip/Knee replacement surgeries, the 19% who used CPAP (OSA) had significantly fewer ER visits and postop complications. https://t.co/kg7oCRndqH https://t.co/WRcxUD3c6V
